NexgenRx Inc. (TSXV:NXG)
Canada · Delayed Price · Currency is CAD | Market Cap | 43.38M +64.9% |
| Revenue (ttm) | 19.34M +12.7% |
| Net Income | 2.37M +162.4% |
| EPS | 0.03 +210.7% |
| Shares Out | 71.12M |
| PE Ratio | 19.68 |
| Forward PE | n/a |
| Dividend | 0.02 (2.46%) |
| Ex-Dividend Date | Aug 28, 2026 |
| Volume | 61,474 |
| Open | 0.6500 |
| Previous Close | n/a |
| Day's Range | 0.6100 - 0.7000 |
| 52-Week Range | 0.2900 - 0.7500 |
| Beta | 0.52 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 20, 2026 |
About NexgenRx
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. The company offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. It also provides proprietary computer software, and ancillary services. NexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada. [Read more]
Financial Performance
In 2025, NexgenRx's revenue was 17.93 million, an increase of 8.84% compared to the previous year's 16.48 million. Earnings were 1.06 million, an increase of 154.16%.
Financial StatementsNews
NexgenRx Announces Second Quarter Results (With Substantial Increases in Revenue, EBITDA and Financial Position) and Declaration of Dividend
TORONTO, ON / ACCESS Newswire / August 20, 2026 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the second quarter ended June 30, 2026, with revenues of ...
NexgenRx Announces Solid Q1 2026 Results with Continued Increasing Revenue, Net Income and EBITDA Growth
TORONTO, ON / ACCESS Newswire / May 21, 2026 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the first quarter ended March 31, 2026, with net income of $...
NexgenRx Announces Declaration of Divdend
TORONTO, ON / ACCESS Newswire / April 17, 2026 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been de...
NexgenRx Announces 2025 Year End Results with Continued Increasing Net Income, EBITDA And Revenue Growth
TORONTO, ON / ACCESS Newswire / March 31, 2026 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the financial year ended December 31, 2025, with ne...
NexgenRx Announces Declaration of Divdends
TORONTO, ON / ACCESS Newswire / December 10, 2025 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been...
NexgenRx Announces Declaration of Dividends
TORONTO, ON / ACCESS Newswire / December 10, 2025 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been...
NexgenRx Announces Significant Third Quarter Revenue and EBITDA Growth
TORONTO, ON / ACCESS Newswire / November 20, 2025 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the third quarter ended September 30, 2025, with quarte...
NexgenRx Announces Declaration of Dividend
TORONTO, ON / ACCESS Newswire / August 15, 2025 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been d...
NexgenRx Announces Second Quarter Results with Significant Revenue Growth and Positive EBITDA
TORONTO, ON / ACCESS Newswire / August 12, 2025 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the second quarter ended June 30, 2025, with quarterly re...
NexgenRx Announces First Quarter Results With Solid Revenue Growth and Positive EBITDA
TORONTO, ON / ACCESS Newswire / May 15, 2025 / NEXGENRX INC. (TSX.V:NXG) ("NexgenRx" or the "Company") is pleased to announce its financial results for the first quarter ended March 31, 2025, with qua...
NexgenRx Announces 2024 Year End Results with Continued Strong Revenue Growth and Increasing Positive EBITDA
TORONTO, ON / ACCESS Newswire / April 3, 2025 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the financial year ended December 31, 2024, with con...
NexgenRx Announces Third Quarter Results and Declaration of Divdend
TORONTO, ON / ACCESSWIRE / November 25, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the third quarter ended September 30, 2024, with quarterly r...
NexgenRX Announces Director Re-Appointment
TORONTO, ON / ACCESSWIRE / October 7, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the re-appointment of Charles Burns to its Board of Directors effective immediately.
NexgenRx Announces New Director
TORONTO, ON / ACCESSWIRE / October 1, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the appointment of Linda Brennan to its Board of Directors effective immediately.
NexgenRx Announces Second Quarter Results, With Over 19% Revenue Growth and Positive EBITDA
TORONTO, ON / ACCESSWIRE / August 15, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the second quarter ended June 30, 2024, with quarterly revenue...
NexgenRx Announces Share Issuances Under Consulting Agreement
TORONTO, ON / ACCESSWIRE / July 18, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the issuance of an aggregate of 195,312 common shares at a price of $0.32 in respect of th...
NexgenRx Announces First Quarter Results, with 24% Revenue Growth and Record Earnings
TORONTO, ON / ACCESSWIRE / May 17, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the first quarter ended March 31, 2024, with revenue of $4,292,73...
NexgenRx Announces Annual Meeting Results
TORONTO, ON / ACCESSWIRE / May 16, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the results of its annual and special meeting (the "Meeting") of shareholders, which was he...
NexgenRx Announces 2023 Year End Results With Solid Revenue Growth, Continuing Positive EBITDA
TORONTO, ON / ACCESSWIRE / April 5, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the financial year ended December 31, 2023, with continue...
NexgenRx Announces Director Resignation
TORONTO, ON / ACCESSWIRE / December 29, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") announces the retirement of Dave Bennett from its Board of Directors as he has accepted a senior executive ro...
NexgenRX Announces Declaration of Dividend
TORONTO, ON / ACCESSWIRE / December 20, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been decl...
NexgenRx Inc. Announces Q3 2023 Quarterly Results with Continued Revenue Growth and Positive EBITDA
TORONTO, ON / ACCESSWIRE / November 23, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the third quarter ended September 30, 2023, with con...
Nexgenrx Announces Q2 2023 Quarterly Results (With Continued Revenue Growth), Consulting Agreement and Option Grant
TORONTO, ON / ACCESSWIRE / August 21, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the second quarter ended June 30, 2023, with continued...
NexgenRx Announces Q1 2023 Quarterly Results with Continued Revenue Growth and Positive EBITDA and Announces Election of New Director
TORONTO, ON / ACCESSWIRE / May 18, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the first quarter ended March 31, 2023, with revenues gro...
NexgenRx Announces 2022 Year End Results With Continued Revenue Growth And Positive EBITDA
TORONTO, ON / ACCESSWIRE / April 6, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the financial year ended December 31, 2022, once again hi...